The frequency of strong p53 expression was comparable between immunosuppressed and immunocompetent patients in SCC in situ and BCC, while in invasive SCC the frequency of a strong p53 expression was lower in immunosuppressed than in immunocompetent patients (7.7% (1 out of 13) vs 41.2% (7 out of 17), P=0.04; Table 2). This evidence concerns the gene TP53 and skin basal cell carcinoma.